Applications of oral pharmaceutical composition to preparation of medicament for preventing or treating kidney diseases

A kidney disease and composition technology, applied in the field of medicine, can solve the problems of unacceptable, repeated injections, subcutaneous bleeding and the like for patients, and achieve the effects of convenient taking, reducing the dosage and alleviating the pain of patients

Active Publication Date: 2012-07-04
LUNAN HOPE PHARM CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, low-molecular-weight heparin is used for injection in this treatment plan. The biggest disadvantage of heparin injection preparations in clinical practice is repeated injections. Subcutaneous injections often cause subcutaneous bleeding, which is difficult for patients who need long-term medication.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Applications of oral pharmaceutical composition to preparation of medicament for preventing or treating kidney diseases
  • Applications of oral pharmaceutical composition to preparation of medicament for preventing or treating kidney diseases
  • Applications of oral pharmaceutical composition to preparation of medicament for preventing or treating kidney diseases

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0033] Example 1 Effect of Rosuvastatin and Low Molecular Heparin Compound on Diabetic Nephropathy in Rats

[0034] 1 Establishment of animal model

[0035] 90 male SD rats with a body weight of (250±20) g were selected. After one week of adaptive feeding, all rats were fasted for 12 hours, and streptozotocin (STZ) was intraperitoneally injected once at 65 mg / kg. Before STZ is used, prepare 2% STZ injection with sodium citrate buffer (0.1mol / L, pH4.5), and use it up within 10 minutes. All rats were housed in separate cages in the same animal room and fed with a standard diet. Feed continuously for 2 weeks, measure blood sugar, urine sugar, 24h urine microalbumin and urine β 2 Microglobulin. The selection criteria of rats with diabetic nephropathy (DN) need to meet the following three conditions at the same time: rat blood glucose higher than 16.7mmol / L, urine output more than doubled and urine albumin positive.

[0036] 2 Grouping and administration

[0037] Modeled DN r...

Embodiment 2

[0072] Example 2 Intervention Effect of Rosuvastatin and Heparin Compound on Early Kidney Damage Caused by Hypertension

[0073] 1. Grouping and administration of experimental animals

[0074] 48 male spontaneously hypertensive rats (SHR) of SPF grade, 12 weeks old, weighing 280-300 g, were provided by the Shanghai Experimental Animal Center of the Chinese Academy of Sciences. 4 rats in a cage, fed with standard feed, free to eat and drink, in a constant temperature and quiet environment of 24 ± 2 degrees Celsius. At the same time, another 8 Wistar-Kyoto (WKY) of the same age were set as the normal control group. The hypertensive rats (SHR) were randomly divided into a model group and an administration group, with 8 rats in each group. All groups were intragastrically administered. The specific grouping and administration are as follows:

[0075] Normal control group: the same volume of purified water;

[0076] Model control group: the same volume of sodium carboxymethyl ...

Embodiment 3

[0103] Example 3 Effect of Rosuvastatin and Low Molecular Heparin Compound on Hypertensive Nephropathy

[0104] 1. Establishment of animal model of hypertensive nephropathy

[0105] 48 male spontaneously hypertensive rats (SHR) of SPF grade, 12 weeks old, weighing 280-300 g, were provided by the Shanghai Experimental Animal Center of the Chinese Academy of Sciences. Add 50 mg / L of nitro-L-arginine methyl ester (L-NAME) to the drinking water of all SHR rats. And replace the newly configured water bottle containing L-NAME every Monday, Wednesday, and Friday. On 0d, 14d, and 28d after the start of the experiment, 24h urine was collected from the rats, and the urine protein content was determined. Rat urinary albuminuria "++" was used as a sign of severe hypertensive nephropathy in hypertensive rats (SHR), which was used as a selection criterion for successful modeling.

[0106] 2. Grouping and administration of hypertensive nephropathy rats

[0107] Preferably, 40 rats with h...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of medicines, in particular to the applications of an oral pharmaceutical composition to the preparation of a medicament for preventing or treating kidney diseases including diabetic nephropathy and hypertensive nephropathy. The pharmaceutical composition provided by the invention comprises an active ingredient of rosuvastatin or pharmaceutically acceptable salts thereof and heparin, heparin with low molecular weight or pharmaceutically acceptable salts thereof. Proved by experiments on animal, the pharmaceutical composition provided by the invention has favorable prevention and treatment action on the diabetic nephropathy and the hypertensive nephropathy of mice and has favorable synergy. The pharmaceutical composition can be prepared into solid oral preparations including tablets and capsules according to a conventional preparation technology.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of an oral pharmaceutical composition in the preparation of medicines for preventing or treating kidney diseases. Background technique [0002] Secondary kidney disease refers to kidney damage caused by systemic diseases, of which diabetes and high blood pressure account for a considerable proportion of kidney damage. Moreover, diabetic nephropathy and hypertensive nephropathy are more harmful to the kidneys and should be given full attention. [0003] Diabetes mellitus (DM) is a group of syndromes caused by environmental and genetic factors. It is due to insufficient insulin secretion or reduced sensitivity of target tissues to insulin, which causes a series of metabolic disorders such as sugar, fat and protein. Can cause damage to multiple systems. Diabetic nephropathy (diabetic nephropathy, DN) has become one of the most common complications of diabetes, a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/727A61K31/505A61P13/12A61P3/10A61P9/12
Inventor 赵志全张帅程国良
Owner LUNAN HOPE PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap